RU2528895C2 - Композиции матриксных носителей, способы и применения - Google Patents

Композиции матриксных носителей, способы и применения Download PDF

Info

Publication number
RU2528895C2
RU2528895C2 RU2012104554/15A RU2012104554A RU2528895C2 RU 2528895 C2 RU2528895 C2 RU 2528895C2 RU 2012104554/15 A RU2012104554/15 A RU 2012104554/15A RU 2012104554 A RU2012104554 A RU 2012104554A RU 2528895 C2 RU2528895 C2 RU 2528895C2
Authority
RU
Russia
Prior art keywords
oil
solid phase
implementation
biopolymer
nanoparticles
Prior art date
Application number
RU2012104554/15A
Other languages
English (en)
Russian (ru)
Other versions
RU2012104554A (ru
Inventor
Александр ВОЛ
Орна Грибова
Original Assignee
Ошади Драг Администрейшн Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ошади Драг Администрейшн Лтд. filed Critical Ошади Драг Администрейшн Лтд.
Publication of RU2012104554A publication Critical patent/RU2012104554A/ru
Application granted granted Critical
Publication of RU2528895C2 publication Critical patent/RU2528895C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2012104554/15A 2009-07-09 2010-07-08 Композиции матриксных носителей, способы и применения RU2528895C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22410009P 2009-07-09 2009-07-09
US61/224,100 2009-07-09
PCT/IL2010/000551 WO2011004376A1 (fr) 2009-07-09 2010-07-08 Compositions de support matriciel, procédés et utilisations

Publications (2)

Publication Number Publication Date
RU2012104554A RU2012104554A (ru) 2013-08-20
RU2528895C2 true RU2528895C2 (ru) 2014-09-20

Family

ID=43428853

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2012104554/15A RU2528895C2 (ru) 2009-07-09 2010-07-08 Композиции матриксных носителей, способы и применения

Country Status (14)

Country Link
US (2) US9060932B2 (fr)
EP (1) EP2451442A4 (fr)
CN (2) CN102099011B (fr)
AU (1) AU2010269815B2 (fr)
BR (1) BR112012000379A2 (fr)
CA (1) CA2767342C (fr)
IL (1) IL249939A0 (fr)
IN (1) IN2012DN00311A (fr)
MX (1) MX340134B (fr)
NZ (1) NZ597326A (fr)
RU (1) RU2528895C2 (fr)
SG (2) SG10201403918RA (fr)
WO (1) WO2011004376A1 (fr)
ZA (1) ZA201109321B (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2544166C2 (ru) * 2013-05-14 2015-03-10 Александр Александрович Кролевец Способ получения микрокапсул оксида цинка

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL188647A0 (en) 2008-01-08 2008-11-03 Orina Gribova Adaptable structured drug and supplements administration system (for oral and/or transdermal applications)
IN2012DN00311A (fr) * 2009-07-09 2015-05-08 Oshadi Drug Administration Ltd
RU2532032C1 (ru) * 2013-03-21 2014-10-27 Сергей Алексеевич Успенский Твердофазный способ получения водорастворимого биоактивного нанокомпозита на основе модифицированной меланином соли гиалуроновой кислоты и наночастиц золота
US9168211B2 (en) * 2014-03-28 2015-10-27 Johnson & Johnson Consumer Inc. Method of making an anhydrous, pigmented composition
US10398732B2 (en) 2016-10-13 2019-09-03 Marshall University Research Corporation Compositions and methods for treating striated muscle injury, treating striated muscle atrophy and/or for promoting striated muscle growth
CN108451787B (zh) * 2018-05-23 2020-01-07 上海格兰化妆品有限公司 一种包埋维生素a醇的纳米脂质载体及其制备方法
US20200383932A1 (en) * 2019-06-05 2020-12-10 The Florida International University Board Of Trustees Biotherapy for viral infections using biopolymer based micro/nanogels
CN115389659B (zh) * 2022-08-23 2024-07-16 浙江中医药大学 一种细胞膜键合磁性碳球复合材料及其制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6228377B1 (en) * 1997-08-28 2001-05-08 L'oreal Water-in-oil emulsion containing fused silica and a polysaccharide alkyl ether

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3252859A (en) 1962-10-24 1966-05-24 Masti Kure Company Inc Colloidal silica-oil composition and method of using same
US6551576B1 (en) 1989-12-22 2003-04-22 Bristol-Myers Squibb Medical Imaging, Inc. Container with multi-phase composition for use in diagnostic and therapeutic applications
ES2027518A6 (es) 1990-12-18 1992-06-01 Andromaco Lab Procedimiento para la preparacion de nuevas asociaciones no covalentes polisacarido-proteina con actividad farmacologica.
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5260002A (en) 1991-12-23 1993-11-09 Vanderbilt University Method and apparatus for producing uniform polymeric spheres
US7083572B2 (en) 1993-11-30 2006-08-01 Bristol-Myers Squibb Medical Imaging, Inc. Therapeutic delivery systems
US20040018236A1 (en) 1995-05-08 2004-01-29 Robert Gurny Nanoparticles for oral administration of pharmaceutical agents of low solubility
ES2093562B1 (es) 1995-05-26 1997-07-01 Univ Santiago Compostela Estabilizacion de sistemas coloidales mediante formacion de complejos ionicos lipido-polisacarido.
US5874105A (en) 1996-01-31 1999-02-23 Collaborative Laboratories, Inc. Lipid vesicles formed with alkylammonium fatty acid salts
US6071535A (en) 1996-01-31 2000-06-06 Collaborative Laboratories, Inc. Lipid vesicles formed with alkylammonium fatty acid salts
US6322765B1 (en) 1996-02-15 2001-11-27 Wacker-Chemie Gmbh Process for preparing silicon dioxide
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US20020039594A1 (en) * 1997-05-13 2002-04-04 Evan C. Unger Solid porous matrices and methods of making and using the same
WO1999012640A1 (fr) 1997-09-09 1999-03-18 Select Release, L.C. Particules enrobees, procedes de fabrication et d'utilisation
US6638621B2 (en) 2000-08-16 2003-10-28 Lyotropic Therapeutics, Inc. Coated particles, methods of making and using
FR2773804B1 (fr) 1998-01-19 2000-02-18 Sanofi Sa Polysaccharides de synthese, procede pour leur preparation et compositions pharmaceutiques le contenant
US6656922B2 (en) 1998-05-28 2003-12-02 Mediplex Corporation, Korea Oral delivery of macromolecules
CA2371940C (fr) 1999-03-31 2008-07-15 Janssen Pharmaceutica N.V. Amidon pregelatinise dans une formulation a liberation regulee
US6458387B1 (en) 1999-10-18 2002-10-01 Epic Therapeutics, Inc. Sustained release microspheres
US7195780B2 (en) 2002-10-21 2007-03-27 University Of Florida Nanoparticle delivery system
DE10001172A1 (de) 2000-01-13 2001-07-26 Max Planck Gesellschaft Templatieren von Feststoffpartikeln mit Polymermultischichten
JP4631119B2 (ja) 2000-01-28 2011-02-16 Ｊｓｒ株式会社 疎水化コロイダルシリカの製造方法
US7067116B1 (en) 2000-03-23 2006-06-27 Warner-Lambert Company Llc Fast dissolving orally consumable solid film containing a taste masking agent and pharmaceutically active agent at weight ratio of 1:3 to 3:1
US6548264B1 (en) 2000-05-17 2003-04-15 University Of Florida Coated nanoparticles
JP2004521857A (ja) 2000-06-29 2004-07-22 エミスフェアー・テクノロジーズ・インク 活性剤の送達のための化合物及び組成物
DE50012404D1 (de) 2000-08-11 2006-05-11 Lohmann Animal Health Gmbh W/o Emulsion Adjuvanszuzammensetzungen für Impstoffen
US20020150621A1 (en) 2000-10-16 2002-10-17 Kohane Daniel S. Lipid-protein-sugar particles for drug delivery
FR2819720B1 (fr) 2001-01-22 2004-03-12 Fournier Lab Sa Nouveaux comprimes de fenofibrate
US6698247B2 (en) 2001-05-04 2004-03-02 Corning Incorporated Method and feedstock for making silica by flame combustion
US6828297B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
WO2003055469A1 (fr) 2001-12-21 2003-07-10 Celator Technologies Inc. Vecteur ameliore a base de polymere et de lipide
US20030235619A1 (en) 2001-12-21 2003-12-25 Christine Allen Polymer-lipid delivery vehicles
US20030198666A1 (en) 2002-01-07 2003-10-23 Richat Abbas Oral insulin therapy
WO2003059288A2 (fr) 2002-01-09 2003-07-24 Enzrel, Inc. Administration medicamenteuse par liposomes de composes anti-inflammatoires, antioxydants, aromatiques ou polycycliques
DE60314495T2 (de) 2002-02-07 2008-03-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem Aminosäuresequenzen, die in der lage sind die durchdringung einer biologischen barriere zu erleichtern
US7244498B2 (en) 2002-06-12 2007-07-17 Tda Research, Inc. Nanoparticles modified with multiple organic acids
US7090868B2 (en) 2002-09-13 2006-08-15 University Of Florida Materials and methods for drug delivery and uptake
CA2511530C (fr) 2003-01-06 2013-07-09 Emisphere Technologies, Inc. Therapie d'administration orale d'insuline le soir
US20040242729A1 (en) * 2003-05-30 2004-12-02 3M Innovative Properties Company Stabilized particle dispersions containing surface-modified inorganic nanoparticles
EP1670500A2 (fr) 2003-09-17 2006-06-21 Chiasma, Ltd. Compositions capables de faciliter la penetration a travers une barriere biologique
CA2541445A1 (fr) 2003-10-31 2005-05-12 Teva Pharmaceutical Industries Ltd. Nanoparticules pour la delivrance de medicaments
KR100638041B1 (ko) * 2003-12-24 2006-10-23 주식회사 삼양사 수용성 약물의 경구투여용 나노입자 조성물 및 그의제조방법
WO2006097793A2 (fr) 2004-04-15 2006-09-21 Chiasma, Ltd. Compositions capables de faciliter la penetration a travers une barriere biologique
US7288134B2 (en) 2004-09-10 2007-10-30 International Business Machines Corporation Dumbbell-like nanoparticles and a process of forming the same
US7282194B2 (en) 2004-10-05 2007-10-16 Gp Medical, Inc. Nanoparticles for protein drug delivery
WO2006044660A2 (fr) 2004-10-14 2006-04-27 Vanderbilt University Nanoparticules lipidiques solides fonctionnalisees et procedes de fabrication et d'utilisation associes
WO2006062506A1 (fr) 2004-12-03 2006-06-15 Enzrel, Inc. Administration de composes antioxydants ou anti-inflammatoires au moyen d'un medicament liposomal enrobe de chitosane
EP1922367B1 (fr) 2005-08-09 2016-03-30 University of Sunderland Detection d'empreintes digitales au moyen de particules de silice hydrophobes et procedes de production desdites particules
ES2761937T3 (es) * 2005-10-24 2020-05-21 Magsense Life Sciences Inc Método para preparar micropartículas recubiertas con polímero
WO2007056424A2 (fr) 2005-11-07 2007-05-18 Penwest Pharmaceuticals, Co. Compositions d'emulsion a liberation controlee
WO2008048288A2 (fr) 2005-11-09 2008-04-24 Montana State University Nouvelles nanoparticules et leur utilisation
EP1957113A4 (fr) 2005-11-21 2011-11-09 Medivas Llc Particules polymeriques pour administration de macromolecules et procedes d'utilisation
US20070184076A1 (en) 2006-02-07 2007-08-09 Unger Evan C Liquid-filled nanodroplets for anti-cancer therapy
US7718609B2 (en) 2006-04-12 2010-05-18 Biodel Inc. Rapid acting and long acting insulin combination formulations
IL188647A0 (en) * 2008-01-08 2008-11-03 Orina Gribova Adaptable structured drug and supplements administration system (for oral and/or transdermal applications)
EP2232123B1 (fr) 2008-01-11 2014-09-17 PII Limited Appareil et procédé d'inspection de pipelines utilisant deux modes d'oscillation ultrasoniques différents
IN2012DN00311A (fr) * 2009-07-09 2015-05-08 Oshadi Drug Administration Ltd

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6228377B1 (en) * 1997-08-28 2001-05-08 L'oreal Water-in-oil emulsion containing fused silica and a polysaccharide alkyl ether

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
P. SOMASUNDARAN Encyclopedia of Surface and Colloid Science, том 4, 2006, CRC Press, Taylor&Francis, стр.2773 [онлайн] *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2544166C2 (ru) * 2013-05-14 2015-03-10 Александр Александрович Кролевец Способ получения микрокапсул оксида цинка

Also Published As

Publication number Publication date
US20120100216A1 (en) 2012-04-26
RU2012104554A (ru) 2013-08-20
US9060932B2 (en) 2015-06-23
WO2011004376A1 (fr) 2011-01-13
CN102099011B (zh) 2016-06-01
MX2012000376A (es) 2012-02-28
BR112012000379A2 (pt) 2016-03-29
CA2767342C (fr) 2018-05-01
EP2451442A1 (fr) 2012-05-16
AU2010269815B2 (en) 2015-10-15
US9504648B2 (en) 2016-11-29
AU2010269815A1 (en) 2012-01-19
EP2451442A4 (fr) 2014-02-12
SG177536A1 (en) 2012-03-29
SG10201403918RA (en) 2014-10-30
IL249939A0 (en) 2017-03-30
ZA201109321B (en) 2013-02-27
MX340134B (es) 2016-06-28
CN105997864A (zh) 2016-10-12
CA2767342A1 (fr) 2011-01-13
NZ597326A (en) 2013-05-31
US20150245993A1 (en) 2015-09-03
IN2012DN00311A (fr) 2015-05-08
CN102099011A (zh) 2011-06-15

Similar Documents

Publication Publication Date Title
RU2528895C2 (ru) Композиции матриксных носителей, способы и применения
EP2254590B1 (fr) Méthodes et compositions pour l'administration orale d'insuline
Dmour et al. Natural and semisynthetic polymers in pharmaceutical nanotechnology
Shishir et al. Colonic delivery of pelargonidin-3-O-glucoside using pectin-chitosan-nanoliposome: Transport mechanism and bioactivity retention
EP2209468A1 (fr) Capsules de chitosane à libération prolongée, comprenant du chitosane et de l'acide phytique
KR20060127841A (ko) 음이온 다당을 포함하는 인 시츄 겔을 사용하는 생리적제제의 전달
Shaikh et al. Sodium alginate-based drug delivery for diabetes management: A review
JP2020189870A (ja) 関節を治療するための組成物及びキット
Khvostov et al. Application of natural polysaccharides in pharmaceutics
KR100939983B1 (ko) 히아루론산-소수성 폴리 아미노산 공중합체
EP2473175B1 (fr) Utilisation d'oligosaccharides non digestibles
Bhinge et al. Herbal liposomes: natural network for targeted drug delivery system
Hormozi Plant polysaccharides for orthopedic drug delivery
CN102905693A (zh) 包含至少一种疏水性治疗活性物质和选自唾液酸鞘糖脂、鞘糖脂或唾液酸鞘糖脂和鞘糖脂的混和物的至少一种化合物的水溶性药物组合物
US20050070500A1 (en) Method of modulating release of saccharides and uses thereof
Jangid et al. Engineered inulin-based hybrid biomaterials for augmented immunomodulatory responses
RU2773149C2 (ru) Композиции и способы для защиты от присутствующих в воздухе патогенов и раздражителей
Jain et al. Pectin-Derived Drug Delivery Systems in Respiratory Diseases
Pan et al. Konjac glucomannan exerts regulatory effects on macrophages and its applications in biomedical engineering
IL309255A (en) Preparations containing proteins, biologically active containing microparticle carriers from cellulose
Khulbe A REVIEW ON ORAL INSULIN

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20190709